Aurora Merolla, Rebecca De Lorenzo, Giacomo Paolazzi, Sara Critelli, Mariagrazia Palladini, Sarah Damanti, Giordano Vitali, Valentina Canti, Marta Cilla, Sabina Martinenghi, Elisabetta Falbo, Marica Ferrante, Jacopo Castellani, Giacomo Pacioni, Cristiano Magnaghi, Anna Fumagalli, Mario G Mazza, Francesco Benedetti, Patrizia Rovere-Querini
Coronavirus disease 2019 (COVID-19) may lead to neuropsychiatric sequelae. Palmitoylethanolamide (PEA) is an anti-inflammatory and neuroprotective amide used in depressive syndromes. Here we investigate whether micronized/ultramicronized (m/um) PEA improves neuropsychiatric sequelae in COVID-19 survivors. Patients evaluated at our post-COVID-19 outpatient clinic between February and August 2021 and presenting neuropsychiatric manifestations (n = 98) were offered treatment with m/umPEA 600 mg twice daily for 3 months...
February 22, 2024: International Clinical Psychopharmacology